Additionally, immune checkpoint inhibitors (ICIs) are often used after resistance develops; however, the benefits of ICIs in patients with BRAF V600E mutant NSCLC remain unclear.<h4>Case presentation</h4>We report a case of a 67-year-old man who was clinically diagnosed with lung adenocarcinoma cT2aN3M1c (BRA) stage IVB (BRAF V600E mutation-positive, programmed death-ligand 1; 90%). Here, BRAF is linked to non-small cell lung carcinoma.